The top symptoms of the Omicron COVID-19 variant may differ from symptoms that were common at the start of the pandemic. Omicron may also be less severe than the Delta variant, a study out of the U.K. found.
People with Omicron often report sore throat and a hoarse voice, which were not as prevalent in Delta cases, a . This is true for vaccinated and unvaccinated patients.
People who contracted the Omicron variant were less likely to be hospitalized compared to those with the Delta variant, Zoe Health said in a . Symptoms also lasted for shorter periods – an average of 6.87 days, compared to 8.89 days.
Earlier COVID-19 variants often caused people to lose their sense of smell. The study found that symptom appeared in less than 20% of cases and often days after the first symptoms began. Other serious symptoms that used to be prevalent – like fever, headaches, brain fog and eye soreness – are less prevalent in Omicron cases. However, they can still occur.
The Zoe Health Study, which was supported by grants from the U.K. Government Department of Health and Social Care, tested people in the U.K. who were vaccinated. They tested participants between June 1 and November 27, 2021 – when the Delta variant was dominant – and between Dec. 20, 2021 to Jan. 17, 2022 – when the Omicron variant dominated.
The study collected 62,002 positive tests and looked at those patients' symptoms. In addition to a difference in the length and types of symptoms between the two variants, researchers said Omicron is found far less frequently in the lower respiratory tract. This is where infection can cause more severe symptoms, potentially sending people to the hospital.
They also found Omicron symptoms do not last as long in vaccinated people.
Delta is better at infecting lung cells than Omicron, the study found. And while Omicron appears to be much more transmissible than previous variants, this variant affects fewer organs than Delta, other studies have found, according to Zoe Health.
The Omicron subvariant that was prevalent at the end of 2021 and the start of 2022 was labeled BA.1. There are now Omicron subvariants, labeled BA.4 and BA.5 that appear to be causing a loss of sense of smell or taste again, Dr. Celine Gounder told CBS News.
A similar study from Imperial College London also found that there was lower reporting of loss of sense of smell and taste for the Omicron variant. However, the study which is yet to be peer-reviewed, found there was higher reporting of cold-like and influenza-like symptoms.
The study used data from REACT-1, a widespread survey in the U.K. that collected at-home COVID-19 tests from about 1.5 million participants between 2020 to 2022, and analyzed how symptoms differed between variants and subvariants.
While it is perceived that newer variants like Omicron are milder, Omicron subvariant BA.2 was associated with reporting more symptoms, with greater disruption to daily activities, than the Omicron subvariant BA.1.
Coronavirus Crisis
More"Explosion" of COVID cases in China not due to relaxed rules, WHO says
Senate passes annual defense spending bill
More than 90% of kids have had at least one bout with COVID, CDC says
White House brings back free at-home COVID test orders
China accepts "no way to keep track" of COVID cases as strategy shifts
MoreCaitlin O'Kane
Caitlin O'Kane is a digital content producer covering trending stories for CBS News and its good news brand, The Uplift.
Objective: The objective of this study is to present a novel clinical manifestation of infection with the Omicron variant of the SARS-CoV-2 virus affecting mainly young, vaccinated, and healthy adults. We describe a new group of COVID-19 patients seeking emergency care with symptoms similar to the life-threatening condition epiglottitis. Here, we present a case series and discuss management.
Methods: We performed a retrospective single-center case study of patients diagnosed with COVID-19 who were referred to the Ear, Nose, and Throat Emergency Department (ENT ED) between January 1 and January 23, 2022 with clinical symptoms such as acute odynophagia, severe sore throat, and fever. Ethical approval was obtained from the Swedish Ethical Review Authority (2020-02579). Informed consent was obtained from all patients included in the study.
Results: Twenty patients meeting inclusion criteria were identified. Fifteen patients were fully vaccinated against COVID-19. Four patients needed a short hospitalization for their symptoms. The most common diagnoses were COVID-19-associated acute viral laryngotracheitis and/or viral pharyngitis. Six patients presented with signs of secondary bacterial infection and were put on antibiotics.
Conclusion: Previous variants of SARS-CoV-2 infection affected predominantly the lower respiratory tract and were associated with loss of smell and taste in many patients. The Omicron variant seems to affect predominantly the upper airways and cause acute laryngitis without olfactory dysfunction. In some patients, the clinical manifestation is similar to the symptoms of epiglottitis. In such a case, a prompt examination of the larynx is the gold standard to exclude inflammatory edema in the upper airways. None of the patients described in this study developed epiglottitis. In this study, we discuss the management of acute odynophagia in COVID-19 patients.